10-Q: Plexus Corp. Reports Lower Sales and Profitability in Q2 2024 Amid Market Headwinds

Plexus Corp. experienced a decrease in net sales and profitability in the second quarter of fiscal year 2024 due to market-driven inventory corrections and weaker demand in certain sectors.

Summary

• Plexus Corp.'s net sales for the second quarter of 2024 decreased by 9.7% to $966.9 million compared to $1,070.8 million in the same period last year.
• The company's gross profit also declined to $88.1 million, with a gross margin of 9.1%, down from 9.6% in the prior year.
• Operating income saw a significant decrease of 48.2% to $29.5 million, with an operating margin of 3.0%, compared to 5.3% in the same quarter of the previous year.
• Net income for the quarter was $16.2 million, a substantial decrease from $40.8 million in the prior year.
• Diluted earnings per share decreased to $0.58 from $1.45 in the same quarter of the previous year.
• The company experienced market-driven inventory corrections at customers and weaker demand in the Healthcare/Life Sciences and Industrial sectors.
• Restructuring and other charges of $11.0 million were incurred, including severance and site closure costs, partially offset by insurance proceeds.
• The company's return on invested capital (ROIC) was 9.9%, resulting in an economic return of 1.7%.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to decreased sales, profitability, and increased costs. While there are some positive aspects, the overall tone is cautious and indicates significant challenges.

Positives

• The EMEA segment saw a significant increase in net sales, driven by production ramps for new customers.
• The Aerospace/Defense sector experienced growth in net sales due to increased customer demand and new program ramps.
• The company's cash flow from operations improved to $84.8 million for the six months ended March 30, 2024, compared to $57.2 million in the same period last year.
• Free cash flow improved to $33.3 million for the six months ended March 30, 2024, compared to $7.7 million in the same period last year.
• The company has $261 million available under its revolving credit facility, with the ability to expand to $750 million.

Negatives

• The AMER and APAC segments experienced decreases in net sales due to market-driven inventory corrections and weaker demand.
• The Healthcare/Life Sciences sector saw a significant decrease in net sales due to reduced customer demand and inventory corrections.
• The Industrial sector also experienced a decrease in net sales due to weaker demand and program discontinuations.
• Gross profit and operating income decreased significantly due to lower sales and increased fixed costs.
• The company incurred $11.0 million in restructuring and other charges, impacting profitability.
• The company's return on invested capital (ROIC) and economic return decreased compared to the previous year.

Risks

• Market-driven inventory corrections and weaker demand in certain sectors are expected to be a near-term challenge.
• If market softness continues for extended periods, it could impact future operating results.
• A global minimum tax is anticipated to unfavorably impact existing tax holidays and the effective tax rate beginning in fiscal 2025.
• Interest expense could increase due to increased borrowing and rising interest rates.
• The company faces risks related to customer delays, changes, cancellations, and forecast inaccuracies.
• There are risks associated with excess and obsolete inventory, including potential write-offs.
• The company is exposed to risks related to information technology systems and data security.

Future Outlook

The company expects market-driven inventory corrections and weaker demand in certain sectors to be a near-term challenge that will lessen later in fiscal 2024. They also anticipate a global minimum tax will materially and unfavorably impact their existing tax holidays and effective tax rate beginning in fiscal 2025. Capital expenditures for fiscal 2024 are estimated to be approximately $100.0 million to $120.0 million.

Management Comments

• Management believes the balance sheet is positioned to support potential future challenges presented by macroeconomic pressures.
• Management measures operational performance and allocates resources on a geographic segment basis.
• Management uses a financial model that is aligned with the business strategy and includes an ROIC goal of 15%.

Industry Context

The report indicates that Plexus is facing challenges common in the Electronic Manufacturing Services industry, such as market-driven inventory corrections and fluctuating demand. The company's performance is also affected by broader economic conditions and global tax policy changes.

Comparison to Industry Standards

• Plexus's performance is being impacted by similar trends affecting other EMS providers, such as inventory corrections and demand fluctuations.
• Companies like Jabil and Flex have also reported similar challenges in recent quarters, indicating a broader industry trend.
• Plexus's gross margin of 9.1% is lower than some of its peers, suggesting potential areas for improvement in cost management and pricing strategies.
• The company's ROIC of 9.9% is below its target of 15%, indicating a need to improve capital efficiency and profitability.
• The company's cash cycle days of 91 days is higher than some of its peers, suggesting potential areas for improvement in working capital management.

Corporate Governance

Legal Proceedings

• The company is party to lawsuits in the ordinary course of business, but management does not believe any proceedings will have a material effect on the company's financial position.

Stakeholder Impact

• Shareholders are impacted by the decrease in net income and diluted earnings per share.
• Employees may be affected by restructuring activities and workforce reductions.
• Customers may experience changes in service delivery due to operational adjustments.
• Suppliers may be impacted by changes in procurement and payment terms.
• Creditors may be affected by changes in the company's financial performance and debt levels.

Next Steps

• The company will continue to monitor market conditions and adjust operations as needed.
• The company will continue to evaluate and consider various financing alternatives to supplement financial resources.
• The company will continue to provide a valuation allowance against its net deferred tax assets in each of the applicable jurisdictions going forward until it determines it is more likely than not that the deferred tax assets will be realized.

Key Dates

Keywords

Electronic Manufacturing Services, EMS, Manufacturing, Supply Chain, Healthcare, Industrial, Aerospace, Defense, Financial Results, Quarterly Report